News

Article

Pharmaceutical Technology

Pharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume2021 eBook
Issue 3

Considering Titanium Dioxide Regulatory Changes

EFSA’s evaluation of risk in food products raises implications for drug product formulations.

titanium dioxide

Kateryna Kon/Adobe.Stock.com

Titanium dioxide is widely used for adding opacity and brightness in many products. A May 2021 evaluation from the European Food Safety Authority (EFSA), which declared that titanium dioxide is unsafe for food products, alarmed other industries that rely on the ingredient. Although changes are not required in pharmaceutical products, some supplement and drug manufacturers and their suppliers have considered potential alternatives. 

Read this article in Pharmaceutical Technology’s Regulatory Sourcebook eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 8-9

Citation

When referring to this article, please cite it as J. Markarian, “Considering Titanium Dioxide Regulatory Changes,” Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Behind the Headlines, Episode 18
Related Content